Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 5
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D, Rounis K, Tsigkas AP, Georgiou A, Galanakis N, Tsakonas G, Ekman S, Papadaki C, Monastirioti A, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S. Makrakis D, et al. Among authors: monastirioti a. PLoS One. 2023 Feb 10;18(2):e0277708. doi: 10.1371/journal.pone.0277708. eCollection 2023. PLoS One. 2023. PMID: 36763597 Free PMC article.
Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer.
Papadaki MA, Koutsopoulos AV, Tsoulfas PG, Lagoudaki E, Aggouraki D, Monastirioti A, Koutoulaki C, Apostolopoulou CA, Merodoulaki AC, Papadaki C, Mavroudis D, Agelaki S. Papadaki MA, et al. Among authors: monastirioti a. Cancers (Basel). 2020 Feb 6;12(2):376. doi: 10.3390/cancers12020376. Cancers (Basel). 2020. PMID: 32041353 Free PMC article.
TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications.
Papadaki MA, Monastirioti A, Apostolopoulou CA, Aggouraki D, Papadaki C, Michaelidou K, Vassilakopoulou M, Alexakou K, Mavroudis D, Agelaki S. Papadaki MA, et al. Among authors: monastirioti a. Cancers (Basel). 2022 Feb 18;14(4):1053. doi: 10.3390/cancers14041053. Cancers (Basel). 2022. PMID: 35205801 Free PMC article.
Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D, Rounis K, Tsigkas AP, Georgiou A, Galanakis N, Tsakonas G, Ekman S, Papadaki C, Monastirioti A, Kontogianni M, Gioulbasanis I, Mavroudis I, Agelaki S. Makrakis D, et al. Among authors: monastirioti a. PLoS One. 2023 Nov 9;18(11):e0294384. doi: 10.1371/journal.pone.0294384. eCollection 2023. PLoS One. 2023. PMID: 37943779 Free PMC article.
Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: monastirioti a. PLoS One. 2023 Nov 9;18(11):e0294382. doi: 10.1371/journal.pone.0294382. eCollection 2023. PLoS One. 2023. PMID: 37943834 Free PMC article.
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: monastirioti a. PLoS One. 2021 Jun 1;16(6):e0252537. doi: 10.1371/journal.pone.0252537. eCollection 2021. PLoS One. 2021. PMID: 34061904 Free PMC article.
14 results